Author affiliations: University of Shizuoka and Global Center of Excellence Program, Shizuoka City, Japan (N. Ohashi, Gaowa, Wuritu, F. Kawamori, D. Wu, Y. Yoshikawa); Kochi Institute of Health, Kochi City, Japan (S. Chiya, K. Fukunaga); Shizuoka Institute of Environment and Hygiene, Shizuoka City (F. Kawamori); Muroto Hospital, Muroto, Japan (T. Funato); Kochi Prefectural Aki Hospital, Aki City, Japan (M. Shiojiri, H. Nakajima); Chu-gei Clinic, Aki District, Japan (Y. Hamauzu); National Institute of Infectious Diseases, Tokyo, Japan (A. Takano, H. Kawabata, S. Ando); Okayama Prefectural Institute for Environmental Science and Public Health, Okayama, Japan (T. Kishimoto)
Figure 2. . . Western blot analyses, using recombinant P44-1 protein (rP44-1) and Anaplasma phagocytophilum–infected THP-1 cells as antigens, of serum samples from 2 men, case-patients 1 and 2, who had A. phagocytophilum infection, Kochi Prefecture, Japan. The Escherichia coli, which produced rP44-1, was kindly provided by Yasuko Rikihisa (Ohio State University, Columbus, OH, USA). The rP44-1 and the rabbit hyperimmune serum (positive control serum) were prepared as described (11,12). Results for a negative control (human serum sample) are included. The primary human serum samples tested were diluted 200- to 400-fold; rabbit serum sample (positive control) was diluted 2,000-fold. The goat antihuman IgG and IgM alkaline phosphatase conjugates (Life Technologies, Grand Island, NY, USA) were used as secondary antibodies. Days represent days after symptom onset. rP, rP44-1 antigen; In, infected THP-1; Un, uninfected THP-1 cells.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.